^
Association details:
| Biomarker: | ARID1A deletion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Excerpt:
We treated nude mice bearing ARID1A-deficient and parental MDA-MB-231 breast cancer tumors and ARID1A-depleted and parental HCT116 colon cancer tumors in the opposite flanks with and without oral 0.33 mg/kg BMN673 daily...MDA-MB-231 xenografts, which grew more slowly, were treated with BMN673 for 30 days...BMN673 significantly inhibited tumor growth in ARID1A-deficient cancer cells but not wild-type cell.
DOI:
10.1158/2159-8290.CD-14-0849
